Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2013

View Archived Issues

Taiho presents results from animal studies of TAS-204 in allergic diseases

AM-679 inhibits early capillary degeneration in vivo

GSK-2330672 demonstrates significant effects on bile acid excretion and synthesis in phase I trial

Oral CCX-872 is well tolerated in healthy volunteers

Phase I results demonstrate intravenous LBR-101 to be safe and well tolerated

Eisai reports first clinical data for anti-protofibrilar monoclonal antibody BAN-2401

Novartis reflects on accomplishments of second quarter 2013

Alleanza begins recruitment in pilot study comparing ALZ-1101 to latanoprost

Janssen R&D Ireland prepares and tests novel HCV inhibitors

Reviva Pharmaceuticals describes monoamine transporter inhibitors

HDAC8 inhibitors reported in recent Pharmacyclics patent

French group patents K(2P)2.1 activators for pain

Invion initiates phase II trial of INV-103 in lupus

Chiesi Farmaceutici patent reports development of muscarinic M3 receptor antagonists

FDA and EMA accept Plegridy marketing applications for review

RaQualia and Eli Lilly to further extend the research term of the collaboration

FDA approves Astagraf XL for organ transplant rejection

Synairgen reports biomarker data from phase II study of SNG-001

Phase II study of GDC-0068 under way in gastroesophageal junction cancer

Amphivena Therapeutics completes financing and signs agreement with Janssen

Researchers create zebrafish model of pharmacoresistant epilepsy

Grant supports microRNA work by InteRNA's collaborator UMC St. Radboud

Heptares achieves research milestone in GPCR collaboration with Cubist

Centaurus BioPharma patents novel SERMs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...